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Introduction {#sec005}
============

Thrombotic microangiopathy (TMA) is defined histologically by the presence of arteriolar and/or glomerular thrombosis \[[@pone.0227445.ref001]\] and is a hallmark of a broad spectrum of diseases that affect the vascular endothelium. After kidney transplantation, the incidence of TMA varies between 0.8% and 14% \[[@pone.0227445.ref002]--[@pone.0227445.ref006]\] and occurs as a recurrence of Atypical Hemolytic Uremic Syndrome (aHUS) or as *de novo* disease. Although its histological features are well defined, the clinical etiological diagnosis is challenging because TMA may be associated with several triggers, involving genetic susceptibility \[[@pone.0227445.ref007]--[@pone.0227445.ref009]\] and environmental factors, such as ischemia, antibody-mediated rejection, calcineurin inhibitor (CNI) toxicity and infection \[[@pone.0227445.ref010]\]. TMA clinical manifestation is also heterogeneous, varying from life-threatening systemic hemolysis to lesions restricted to the dysfunctional allograft. Therapeutic options include temporary or definitive CNI withdrawal, plasma exchange therapy, treatment of the underlying triggering factor(s), and use of complement system blockers \[[@pone.0227445.ref011]\]. Overall, post-transplant TMA has been associated with poor allograft outcomes with up to 40% of graft loss \[[@pone.0227445.ref002],[@pone.0227445.ref012]\].

Considering the TMA significant negative impact on graft survival, advances in the understanding of its clinical presentation, underlying pathogenesis and prognostic features is fundamental to devise more effective and safety preventive and therapeutic strategies. Previous studies in children with HUS revealed that specific histological lesions in native kidney predicted development of chronic kidney disease \[[@pone.0227445.ref013]--[@pone.0227445.ref018]\]. In the post-transplant setting, it remains unclear whether the TMA histological patterns and clinical presentation have distinct pathogenic mechanisms and, ultimately, result in different clinical outcomes. \[[@pone.0227445.ref002],[@pone.0227445.ref003],[@pone.0227445.ref019]--[@pone.0227445.ref020]\]

The aim of the present study was to present the clinical features and pathologic changes of TMA in a cohort of kidney or kidney-pancreas transplanted recipients who developed TMA, and correlate them with allograft outcomes.

Patients and methods {#sec006}
====================

Study design and population {#sec007}
---------------------------

In this retrospective cohort study, we initially retrieved all consecutive unselected reports of renal transplant biopsies from Hospital do Rim database between January 2011 and December 2015. These biopsies were performed for graft dysfunction, new onset proteinuria or delayed graft function from kidney and kidney-pancreas transplanted patients. Of a total of 6886, we selected 119 biopsies whose reports described features of TMA. Final diagnosis was confirmed by one of the pathologist authors (LARM).

All data were fully anonymized before accessed. The protocol adheres to the 2000 Declaration of Helsinki as well as the Declaration of Istanbul 2008. The institutional review board (Comitê de Ética em Pesquisa-CEP-UNIFESP) waved the requirement for informed consent and approved this study (protocol number 1643995).

Histological features of TMA {#sec008}
----------------------------

TMA was defined as the presence of occlusive fibrin-platelet thrombi in at least one glomerulus and/or renal arteriole/artery on renal transplant biopsies. Tissues for light microscopy were fixed in 4% formaldehyde, embedded in paraffin using routine procedure. Three to five-micrometer thick sections were cut from the tissue blocks and stained with hematoxylin-eosin, Masson's Trichrome with aniline blue, and Jones\' silver staining. Acute cellular rejection and interstitial fibrosis and tubular atrophy (IF/TA) index were graded according to the Banff'13 criteria \[[@pone.0227445.ref021]\]. The extent of involvement of peritubular capillaries by linear deposition of C4d using the monoclonal antibody or by immunochemistry using polyclonal antibody was also recorded and correlated with histology and donor-specific antibody for the diagnosis of ABMR.

Because morphological features, such as extent of histopathological involvement and presence of mesangiolysis, were associated with native kidney disease severity in patients with HUS \[[@pone.0227445.ref013]--[@pone.0227445.ref017]\], we hypothesized that TMA histological patterns may have prognostic value. Therefore, TMA lesions were classified into the following categories according to thrombi location: (1) glomerular TMA showing thrombi only in afferent or efferent arteriole or glomerular capillary; (2) arteriolar TMA showing thrombi only in arterioles or interlobular arteries; (3) glomerular/arteriolar TMA, when both glomerulus and arterioles were affected. The probable pattern of injury was also classified as (1) thrombotic lesions, when the only TMA feature was the presence of thrombi and (2) endothelial cell activation, defined by one or more of the following features: mesangiolysis, capillary necrosis, glomerular endothelial detachment, capillary wall thickening (obliterative arteriolopathy) defined as luminal occlusion with mural myxoid or fibrinoid change and thickening of the vessel wall. All biopsies were reviewed by the same pathologist for this study.

Clinical presentation of TMA {#sec009}
----------------------------

TMA precipitating factors were retrospectively adjudicated and classified according to the following not mutually exclusive categories: (1) acute rejection: biopsy-proven acute cellular rejection (TCMR) or acute antibody-mediated rejection (ABMR) within one week; (2) infection: infectious complication within one week; (3) pregnancy; (4) CNI toxicity: improvements in allograft function when CNI withdrawal was the only intervention. When HUS or thrombocytopenic thrombotic purpura (TTP) was the cause of the primary kidney disease, TMA was considered recurrent.

Systemic or localized TMA was defined based on the presence or not of: thrombocytopenia (platelets \<150x10^3^/mL) with microangiopathic hemolysis (either schistocytes on peripheral-blood smear, haptoglobin \<15 mg/dL or lactate dehydrogenase \>1,000 U/L) \[[@pone.0227445.ref003]\], at the time of the allograft biopsy diagnostic of TMA.

Finally, the timing of TMA presentation was classified as early (≤90 days) or late (\>90 days), considering that the highest risk of both *de novo* and recurrent TMA is between 3 and 6 months after transplantation \[[@pone.0227445.ref022]\].

Clinical and laboratory data {#sec010}
----------------------------

Demographic baseline information, TMA presentation and management after the diagnosis were obtained by retrospective chart review. Estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation \[[@pone.0227445.ref023]\].

Outcomes variables {#sec011}
------------------

The outcome variables were analyzed after 12 months of follow-up after TMA diagnosis and included patient and graft survivals and renal graft function (eGFR). Allograft function was also compared at baseline (lowest serum creatinine within 3 months before TMA), at TMA diagnosis and at one-year after TMA. Patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. Causes of graft loss were collected and classified as acute rejection, IF/TA, recurrent or *de novo* glomerular disease, or thrombotic microangiopathy \[[@pone.0227445.ref024]\].

Comparisons of allograft function and survival were made according to the following characteristics: presence of hemolysis (Systemic vs. Localized TMA), time of onset (Early vs. Late onset TMA), association with acute ABMR, alone or combined with cellular rejection (TMA with vs. without ABMR), thrombi location (Glomerular, Arteriolar or Glomerular/Arteriolar TMA) and pattern of renal injury (Thrombotic vs. Endothelial cell activation).

Statistical analyses {#sec012}
--------------------

Incidence density was estimated by dividing the number of patients that fulfilled criteria for TMA by the sum of the follow-up times for each individual at risk during the study period and reported as n/1,000 person-years. Kaplan-Meier patient survival and death-censored survival plots were used and log-rank test was performed for comparison between groups. Differences in allograft function were analyzed by two-way ANOVA (Bonferroni post-hoc test) for parametric data and Mann-Whitney or Kruskal-Wallis (Dunn-Bonferroni post-hoc test) for nonparametric data. A two-sided P-value \<0.05 was considered statistically significant. All analyses were conducted with SPSS version 22 (IBM, Armonk, NY, USA) and STATA version 12.0.

Results {#sec013}
=======

Incidence {#sec014}
---------

Of 9,541 patients at risk, 119 patients were diagnosed with TMA in renal allograft during the study period. After pathology review, 10 patients did not fulfill the histopathologic TMA criteria and 4 were unavailable for review. Individuals with TMA associated to acute glomerulonephritis (n = 1), renal/arterial thrombosis (n = 4), donor kidney with thrombi due to disseminated intravascular coagulation (DIC) (n = 4), diagnosed only after allograft nephrectomy (n = 5) or whose clinical data were unavailable (n = 2) were excluded ([Fig 1](#pone.0227445.g001){ref-type="fig"}). Therefore, a total of 89 patients fulfilled the study criteria, yielding a cumulative incidence of 0.93% and an incidence density of 1.8 cases/1,000 person-years.

![Casuistic selection flowchart.\
Allograft biopsies of kidney or pancreas-kidney transplanted patients with suspected TMA were reviewed by the same pathologist. Confirmed TMA was defined as the presence of occlusive fibrin-platelet thrombi in at least one glomerulus and/or arteriole. TMA = Thrombotic microangiopathy.](pone.0227445.g001){#pone.0227445.g001}

Baseline characteristics {#sec015}
------------------------

The majority of the recipients were young adults, female and Caucasian with primary kidney disease due to unknown etiology ([Table 1](#pone.0227445.t001){ref-type="table"}). A high proportion of patients had pretransplant panel-reactive antibodies (PRA) Class I and Class II \<50%, 90% and 92% respectively. Most individuals received the kidney transplant from a deceased-donor (68%). While 61% received induction therapy, 99% were maintained with CNI in combination with antimetabolite (87%) or mammalian target of rapamycin (mTOR) inhibitor (12%).

10.1371/journal.pone.0227445.t001

###### Baseline characteristic of TMA cases (n = 89).

![](pone.0227445.t001){#pone.0227445.t001g}

  Variables                                                                                        Values
  ------------------------------------------------------------------------------------------------ -------------
  [Recipient Gender, *female*, n (%)]{.ul}                                                         46 (52%)
  [Recipient Age, *years---*mean ± SD]{.ul}                                                        39 ± 14
  [Recipient Race, n (%)]{.ul}                                                                     
      *Caucasian*                                                                                  43 (48%)
      *Mixed*                                                                                      28 (32%)
      *Black*                                                                                      14 (16%)
      *Others*                                                                                     4 (4%)
  [Causes of chronic kidney disease, n (%)]{.ul}                                                   
      *Glomerulonephritis*                                                                         17 (19%)
      *HUS or TTP*                                                                                 2 (2%)
      *Undetermined*                                                                               33 (37%)
      *Diabetes Mellitus*                                                                          13 (15%)
      *Others*                                                                                     24 (27%)
  ^[&]{.ul}^[Time on dialysis, *months*---median (range)]{.ul}                                     24 (0--217)
  [Historic peak PRA, n (%)]{.ul}                                                                  
      [Class I]{.ul}                                                                               
      *0%*                                                                                         64 (71%)
      *1--10%*                                                                                     5 (6%)
      *11--30%*                                                                                    5 (6%)
      *31--50%*                                                                                    6 (7%)
      *\>50%*                                                                                      9 (10%)
      [Class II]{.ul}                                                                              
      *0%*                                                                                         72 (81%)
      *1--10%*                                                                                     3 (3%)
      *11--30%*                                                                                    5 (6%)
      *31--50%*                                                                                    2 (2%)
      *\>50%*                                                                                      7 (8%)
  [Preexisting HLA-DSA MFI \> 300, n(%)]{.ul}                                                      10 (11%)
  [HLA mismatches, (mean ± SD)]{.ul}                                                               2.5 ± 1.4
  [Re-transplant, n (%)]{.ul}                                                                      6 (7%)
  [\*](#t001fn002){ref-type="table-fn"}[Pre-transplant AT1R antibodies (\> 17UI/mL), n (%)]{.ul}   16 (18%)
  [Donor age, *years*- median (range)]{.ul}                                                        47 (5--70)
  [Donor Gender, *female*, n (%)]{.ul}                                                             53 (60%)
  [Donor Race, n (%)]{.ul}                                                                         
      *Caucasian*                                                                                  50 (56%)
      *Mixed*                                                                                      28 (32%)
      *Black*                                                                                      11 (12%)
  [Donor type, n (%)]{.ul}                                                                         
      *Living*                                                                                     28 (32%)
      *Deceased standard-criteria*                                                                 41 (46%)
      *Deceased expanded-criteria*                                                                 17 (19%)
      *Pancreas-Kidney*                                                                            3 (3%)
  [Induction immunosuppressive treatment, n (%)]{.ul}                                              
      *Basiliximab*                                                                                17 (19%)
      *Anti-thymocyte globulin*                                                                    37 (42%)
      *None*                                                                                       35 (39%)
  [Maintenance immunosuppressive treatment, n (%)]{.ul}                                            
      *Tacrolimus/Cyclosporine + Prednisone + AZA/MPS*                                             77 (87%)
      *Tacrolimus/Cyclosporine + Prednisone + Everolimus/Sirolimus*                                11 (12%)
      *Others*                                                                                     1 (1%)

& out of 88 patients

\* out of 87 patients

TMA = thrombotic microangiopathy; SD = standard deviation; HUS = hemolytic uremic syndrome; TTP = thrombocytopenic thrombotic purpura; PRA = panel-reactive antibodies; HLA = human leukocyte antigens; DSA = donor-specific antibody; MFI = mean fluorescence intensity; AT1R = angiotension II type 1 receptor; AZA = azathioprine; MPS = mycophenolate sodium

TMA clinical presentation {#sec016}
-------------------------

The median time to TMA diagnosis was 3 months post transplant and 51% occurred before 3 months ([Table 2](#pone.0227445.t002){ref-type="table"}). The proportion of patients receiving CNI in combination with antimetabolite decreased to 67% but did not change significantly with mTOR inhibitor (14%). At the time of TMA diagnosis, the median eGFR was 17 ml/min/1.73m^2^ and 36% of the patients (n = 32) were on dialysis.

10.1371/journal.pone.0227445.t002

###### Clinical features of TMA onset (n = 89).

![](pone.0227445.t002){#pone.0227445.t002g}

  Variables                                                                                       Values
  ----------------------------------------------------------------------------------------------- ------------
  [Post transplant months, median (range)]{.ul}                                                   3 (0--129)
  [Early onset TMA, n (%)]{.ul}                                                                   45 (51)%
  [Immunosuppressive at diagnosis, n (%)]{.ul}                                                    
      *Tacrolimus/Cyclosporine + Prednisone + AZA/MPS*                                            64 (72%)
      *Tacrolimus/Cyclosporine + Prednisone + Everolimus/Sirolimus*                               12 (14%)
      *Tacrolimus + Prednisone*                                                                   10 (11%)
      *Others*                                                                                    3 (3%)
  [eGFR (ml/min/1.73m]{.ul}^[2]{.ul}^[), median (range)]{.ul}                                     17 (4--67)
  [^@^](#t002fn001){ref-type="table-fn"}[Proteinuria ≥ 1g/dL/day, n (%)]{.ul}                     40 (56%)
  [Hemolysis, n (%)]{.ul}                                                                         22 (25%)
      [\*](#t002fn002){ref-type="table-fn"}*Hemoglobin levels (g/dL)---mean ± SD*                 8.7 ± 1.5
      [\*](#t002fn002){ref-type="table-fn"}*Platelet count nadir (x 1*,*000/mL)---mean ± SD*      95 ± 46
      [\*](#t002fn002){ref-type="table-fn"}*Lactate dehydrogenase (UI/L)- mean ± SD*              682 ± 460
      [\*](#t002fn002){ref-type="table-fn"}*Lactate dehydrogenase peak \> 1*,*000UI/L*, *n (%)*   6 (27%)
      [^%^](#t002fn003){ref-type="table-fn"}*Schistocytes*, *n (%)*                               20 (95%)
      [^&^](#t002fn004){ref-type="table-fn"}*Reduced haptoglobin*, *n (%)*                        9 (53%)
  [Concomitant acute rejection, n (%)]{.ul}                                                       30 (34%)
      *Cellular rejection*                                                                        18 (21%)
      *Antibody-mediated rejection*                                                               9 (10%)
      *Mixed rejection*                                                                           3 (3%)
  [Pregnancy at diagnosis, n (%)]{.ul}                                                            3 (3%)
  [Concomitant infection, n (%)]{.ul}                                                             48 (54%)
      *Urinary tract infection*                                                                   11 (13%)
      *Cytomegalovirus*                                                                           5 (6%)
      *Bloodstream infection*                                                                     3 (3%)
      *Pneumonia*                                                                                 4 (5%)
      *Donor-derived infection*                                                                   3 (3%)
      *Gastrointestinal*                                                                          2 (2%)
      [^\#^](#t002fn005){ref-type="table-fn"}*Others*                                             9 (10%)
      *More than one site*                                                                        11 (12%)

@ out of 72 patients whose proteinuria data was available.

\* out of 22 patients with hemolysis

\% out of 21 patients tested for schistocyte

& out of 17 patients tested for haptoglobin

\# syphilis (n = 1), tuberculosis (n = 1), cryptococcosis (n = 2), dental abscess (n = 1), polyoma virus (n = 3), empirical infection treatment (n = 4).

TMA = thrombotic microangiopathy; AZA = azathioprine; MPS = mycophenolate sodium; eGFR = estimated Glomerular Filtrate Rate; SD = standard deviation.

The most common identified triggers were infection, in 54% of the patients, and acute rejection, in 34%. CNI toxicity occurred in 13% of the patients and pregnancy, in 3%. 18% of the patients had more than one precipitating condition and, in 17%, no factor was identified. In 2% of the patients, TMA was recurrent.

Of all ABMR episodes (n = 12), 2 were associated with antibodies to angiotensin II type 1 receptor (AT1R) and one with an ABO-incompatible transplant. Urinary tract infection was the most common infection (17%) followed by cytomegalovirus and blood stream infections. The three patients who were pregnant had a TMA diagnosis with a mean gestation time of 15 weeks. Of them, two developed preeclampsia with HELLP syndrome (hemolysis, elevated liver enzymes and low platelets). The mean gestational time at delivery was 22 weeks, resulting in two abortions and one stillbirth, and two graft losses within 12 months of follow-up.

Systemic TMA occurred in 25% of the patients, being their mean hemoglobin and platelet levels 8.7±1.5g/dL and 95±46 x 10^3^/μL, respectively, and the presence of schistocytes (95%) and reduced haptoglobin (53%) were the most common hemolysis criteria found ([Table 2](#pone.0227445.t002){ref-type="table"}).

TMA histological presentation {#sec017}
-----------------------------

Glomerular TMA was the most prevalent lesion (71%), either alone (50%) or combined with arteriolar lesions (21%). Features of endothelial cell activation were observed in 61% of the biopsies. Concomitant acute cellular rejection was present in 19%. Moderate to severe IF/TA was present in 47% of the biopsy specimens ([Table 3](#pone.0227445.t003){ref-type="table"}).

10.1371/journal.pone.0227445.t003

###### Histopathological features of TMA cases (N = 89).

![](pone.0227445.t003){#pone.0227445.t003g}

  --------------------------------------------------------------------
  Variable                                                  Values
  --------------------------------------------------------- ----------
  [Number of glomerulus, mean ± SD]{.ul}                    12 ± 6

  [Mesangiolysis, n (%)]{.ul}                               28 (31%)

  [Thrombi location, n (%)]{.ul}                            

      *Glomerular*                                          44 (50%)

      *Arteriolar*                                          26 (29%)

      *Both*                                                19 (21%)

  [Morphological presentation, n (%)]{.ul}                  

      *Endothelial cell activation*                         54 (61%)

      *Only thrombotic*                                     35 (39%)

  [Acute Rejection, n (%)]{.ul}                             

      *None*                                                59 (66%)

      *Cellular rejection 1A*                               3 (3%)

          *1B*                                              7 (8%)

          *2A*                                              4 (5%)

              *2B*\                                         4 (5%)\
      *Antibody-mediated rejection*\                        9 (10%)\
      *Mixed rejection*                                     3 (3%)

  [C4d, n (%)]{.ul}                                         

      *Immunofluorescence positive*                         13 (15%)

      *Immunohistochemistry negative*                       22 (25%)

      *Immunofluorescence negative*                         33 (37%)

      *Not performed*                                       21 (23%)

  [Tubular atrophy and interstitial fibrosis, n (%)]{.ul}   

      *None*                                                3 (3%)

      *Mild*                                                45 (51%)

      *Moderate*                                            36 (41%)

      *Severe*                                              5 (6%)
  --------------------------------------------------------------------

TMA = thrombotic microangiopathy; SD = standard deviation.

Treatment after TMA {#sec018}
-------------------

Management after TMA diagnosis was based on multiples treatments. In general, CNI withdrawal was performed in 54% of patients and plasmatherapy in 22%. In 11% of the patients, expectant management was preferred. Allograft nephrectomy was carried out in 12% of them.

Among the patients with TMA associated to rejection (N = 30), 93% received treatment for acute rejection according to the institution protocols, 37% also had the CNI withdrawal, in 20% plasmatherapy was performed and 27% also needed allograft nephrectomy due to persistent hemolysis. The patients with TMA and concomitant infection treatment (N = 48) also had supportive care as CNI cessation (60%), plasmatherapy (29%) and allograft nephrectomy (17%). Among the three pregnant patients with TMA, two had CNI withdrawal and one was subjected to plasmatherapy. The two patients with recurrent TMA were treated with plasmapheresis and CNI withdrawal, and one of them had allograft nephrectomy.

Outcomes {#sec019}
--------

Three patients died from infectious complications, at a mean time between TMA diagnosis and death of 162 days, yielding a 1-year 97% patient survival. Corresponding graft survival was 66% ([Fig 2](#pone.0227445.g002){ref-type="fig"}). The primary causes of graft loss were TMA (43%), followed by acute rejection (30%) and IF/TA (24%). There was one case of focal segmental glomerulosclerosis recurrence (3%). There was allograft loss within the first 3 months post transplant in 13 patients (15%).

![Kaplan-Meier death-censored graft survival of kidney or pancreas-kidney transplanted patients with TMA (n = 89).\
Survival outcomes were analysed after one-year of TMA diagnosis. TMA = Thrombotic microangiopathy.](pone.0227445.g002){#pone.0227445.g002}

Allograft survival was inferior in the presence of ABMR (with 70% vs. without 41%, p = 0.01) ([Fig 3](#pone.0227445.g003){ref-type="fig"}). There were no statistical differences in allograft survival comparing patients with or without hemolysis (59% vs. 69%, p = 0.42), with early or late presentation (62% vs. 71%, p = 0.35), with glomerular, arteriolar or glomerular and arteriolar thrombi location (68% vs. 73% vs. 53%, p = 0.19) and with endothelial cell activation or only thrombotic lesions (63% vs. 71%, p = 0.46).

![Kaplan-Meier death-censored graft survival of kidney or pancreas-kidney transplanted patients with TMA associated or not with ABMR.\
Patients with TMA associated with ABMR had a statistically significant higher incidence of graft loss (with ABMR vs. without ABMR, p = 0.01-log-rank test). TMA = Thrombotic microangiopathy; ABMR = antibody-mediated rejection.](pone.0227445.g003){#pone.0227445.g003}

Mean eGFR was 36.9±25.9ml/min/1.73 m^2^ at baseline, 20.6±15.5 ml/min/1.73 m^2^ at TMA diagnosis and 28.6±23.7 ml/min/1.73 m^2^ one year after (p\<0.001, [Table 4](#pone.0227445.t004){ref-type="table"}).

10.1371/journal.pone.0227445.t004

###### Evolution of eGFR in time of patients with TMA (mean±SD).

![](pone.0227445.t004){#pone.0227445.t004g}

                                       Timeline                                                                                                                                                                
  ------------------------------------ ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ----------
  [Total (n = 89)]{.ul}                36,94 ± 25,94[^a\'^](#t004fn003){ref-type="table-fn"}   20,64 ± 15,46[^b\'^](#t004fn003){ref-type="table-fn"}   28,64 ± 23,69[^b\'^](#t004fn003){ref-type="table-fn"}   \<0,001§
  [Hemolysis]{.ul}                                                                                                                                                                                             
      with (n = 22)                    39,16 ± 25,53[^a\'^](#t004fn003){ref-type="table-fn"}   22,15 ± 15,10[^b\'^](#t004fn003){ref-type="table-fn"}   29,11 ± 23,82[^b\'^](#t004fn003){ref-type="table-fn"}   \<0,001§
      without (n = 67)                 30,20 ± 26,58[^a\'^](#t004fn003){ref-type="table-fn"}   16,06 ± 16,01[^b\'^](#t004fn003){ref-type="table-fn"}   27,20 ± 23,77                                           0,007§
  [Onset]{.ul}                                                                                                                                                                                                 \<0,001
      Early (n = 45)                   27,08 ± 25,40[^a^](#t004fn002){ref-type="table-fn"}     17,16 ± 15,42[^b^](#t004fn002){ref-type="table-fn"}     30,92 ± 27,01[^a^](#t004fn002){ref-type="table-fn"}     
      Late (n = 44)                    47,02 ± 22,61[^a^](#t004fn002){ref-type="table-fn"}     24,20 ± 14,85[^b^](#t004fn002){ref-type="table-fn"}     26,32 ± 19,77[^b^](#t004fn002){ref-type="table-fn"}     
  [Antibody-mediated rejection]{.ul}                                                                                                                                                                           
      with (n = 12)                    38,69 ± 25,76[^a\'^](#t004fn003){ref-type="table-fn"}   21,88 ± 15,58[^b\'^](#t004fn003){ref-type="table-fn"}   29,19 ± 22,38[^b\'^](#t004fn003){ref-type="table-fn"}   \<0,001§
      without (n = 77)                 25,72 ± 25,28[^a\'^](#t004fn003){ref-type="table-fn"}   12,71 ± 12,52[^b\'^](#t004fn003){ref-type="table-fn"}   25,13 ± 31,85[^a\'^](#t004fn003){ref-type="table-fn"}   0,011§
  [Thrombi location]{.ul}                                                                                                                                                                                       \<0,001
      Glomerular (n = 44)              37,47 ± 22,49[^a^](#t004fn002){ref-type="table-fn"}     24,24 ± 14,53[^c^](#t004fn002){ref-type="table-fn"}     27,47 ± 20,41[^b^](#t004fn002){ref-type="table-fn"}     
      Arteriolar (n = 26)              41,83 ± 28,20[^a^](#t004fn002){ref-type="table-fn"}     20,92 ± 15,41[^c^](#t004fn002){ref-type="table-fn"}     33,32 ± 25,38[^b^](#t004fn002){ref-type="table-fn"}     
      Both (n = 19)                    24,89 ± 21,78[^a^](#t004fn002){ref-type="table-fn"}     15,08 ± 16,02[^c^](#t004fn002){ref-type="table-fn"}     19,41 ± 21,91[^b^](#t004fn002){ref-type="table-fn"}     
  [Endothelial cell activation]{.ul}                                                                                                                                                                            \<0,001
      with (n = 54)                    44,59 ± 28,74[^a^](#t004fn002){ref-type="table-fn"}     23,25 ± 15,64[^c^](#t004fn002){ref-type="table-fn"}     35,21 ± 25,64[^b^](#t004fn002){ref-type="table-fn"}     
      without (n = 35)                 31,99 ± 22,88[^a^](#t004fn002){ref-type="table-fn"}     18,95 ± 15,25[^c^](#t004fn002){ref-type="table-fn"}     24,39 ± 21,52[^b^](#t004fn002){ref-type="table-fn"}     

p---Time effect by ANOVA or Friedman nonparametric test (§)

a, b e c---ANOVA (post-hoc test Bonferroni) differences between mean values in time.

a\', b\' e c\'---Friedman / Mann-Whitney or Kruskal-Wallis (post-hoc test Dunn-Bonferroni) differences between mean values in time.

TMA = thrombotic microangiopathy; eGFR = estimated Glomerular Filtrate Rate; SD = standard deviation

Hemolysis, association to ABMR, thrombi location or presence of endothelial cell activation did not correlate to behavior of allograft function in time. (Figs [4](#pone.0227445.g004){ref-type="fig"}--[9](#pone.0227445.g009){ref-type="fig"}). Patients with a late onset TMA had a different behavior than the ones with an early TMA, given that, despite of having a higher eGFR at baseline, their allograft function did not returned to baseline after one-year of TMA diagnosis (p = 0,01). [Table 4](#pone.0227445.t004){ref-type="table"}. The lower eGFR in early onset group at baseline can be partially explained by the high percentage of patients with delayed or unsatisfactory allograft function (55% of 45 with early TMA).

![Allograft function of kidney-transplanted patients with TMA at baseline, TMA diagnosis and after one-year of follow-up (n = 89).\
A statistically significant drop of mean eGFR±SE occurred at diagnosis (Baseline vs. Diagnosis, p\<0.001), which was permanent until the end of the study (Diagnosis vs. One-year after, p = 0.13; Baseline vs. One-year after, p\<0.001). Baseline eGFR was calculated with the lowest serum creatinine level in up to 3 months before TMA diagnosis and patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. \* means p\< 0.05 in relation to baseline eGFR. TMA = Thrombotic microangiopathy; eGFR = estimated glomerular filtration rate; SE = standard error.](pone.0227445.g004){#pone.0227445.g004}

![Allograft function of kidney-transplanted patients with TMA at baseline, TMA diagnosis and after one-year of follow-up, according to the presence of hemolysis.\
Hemolysis was associated with a lower mean eGFR±SE at TMA diagnosis (Systemic vs. Localized TMA at diagnosis-p = 0.04), however at the end of follow-up, there was no difference between groups (Systemic vs. Localized TMA one-year after- p = 0.76). Systemic TMA was defined by the presence of anemia, plaquetopenia and DHL\> 1,000 U/L or schistocyte or reduced haptoglobin. Baseline eGFR was calculated with the lowest serum creatinine level in up to 3 months before TMA diagnosis and patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. TMA = Thrombotic microangiopathy; eGFR = estimated glomerular filtration rate; SE = standard error.](pone.0227445.g005){#pone.0227445.g005}

![Allograft function of kidney-transplanted patients with TMA at baseline, TMA diagnosis and after one-year of follow-up, according to the time of onset.\
Patients with a early onset TMA had a lower eGFR±SE at baseline (Early onset vs. Late onset TMA at baseline, p = \<0.001), nevertheless, after one year following TMA diagnosis the allograft function was similar in both groups (Early onset vs. Late onset TMA one-year after, p = 0.31) Early onset TMA was defined when it occurred less than 3 months post-transplant. Baseline eGFR was calculated with the lowest serum creatinine level in up to 3 months before TMA diagnosis and patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. TMA = Thrombotic microangiopathy; eGFR = estimated glomerular filtration rate; SE = standard error.](pone.0227445.g006){#pone.0227445.g006}

![Allograft function of kidney-transplanted patients with TMA at baseline, TMA diagnosis and after one-year of follow-up, according to the presence of ABMR.\
Patients with TMA associated to ABMR had a mean eGFR lower at baseline, which was persistent until the end of follow-up (p = 0.08). On follow-up, the allograft function was similar in patients with or without AMR (p = 0.257). Baseline eGFR was calculated with the lowest serum creatinine level in up to 3 months before TMA diagnosis and patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. TMA = Thrombotic microangiopathy; ABMR = Antibody Mediated Rejection; eGFR = estimated glomerular filtration rate; SE = standard error.](pone.0227445.g007){#pone.0227445.g007}

![Allograft function of kidney-transplanted patients with TMA at baseline, TMA diagnosis and after one-year of follow-up, according to the thrombi location.\
Patients with thrombi located in both arterioles and glomerulus had a lower eGFR±SE than those whose thrombi located only in arterioles at all moments of observation (Arteriolar TMA vs. Arteriolar and Glomerular TMA, p = 0.008). TMA glomerular was defined when thrombi was located in afferent and efferent arteriole or glomerular capillary and TMA arteriolar, when it was located in arterioles or interlobular arteries. Baseline eGFR was calculated with the lowest serum creatinine level in up to 3 months before TMA diagnosis and patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. TMA = Thrombotic microangiopathy; eGFR = estimated glomerular filtration rate; SE = standard error.](pone.0227445.g008){#pone.0227445.g008}

![Allograft function of kidney-transplanted patients with TMA at baseline, TMA diagnosis and after one-year of follow-up, according to presence endothelial cell activation (EC activation).\
Patients with TMA lesions with EC activation had a lower eGFR±SE, at all moments of observation (with vs. without, p = 0.013). EC activation was defined when there was mesangiolysis, capillary necrosis, glomerular endothelial detachment, capillary wall thickening obliterative arteriolopathy defined as luminal occlusion with mural myxoid or fibrinoid change, thickening of the vessel wall. Baseline eGFR was calculated with the lowest serum creatinine level in up to 3 months before TMA diagnosis and patients with graft failure were considered to have an eGFR of 5 ml/min/1,73m^2^. TMA = Thrombotic microangiopathy; eGFR = estimated glomerular filtration rate; SE = standard error.](pone.0227445.g009){#pone.0227445.g009}

Discussion {#sec020}
==========

Our study emphasizes the poor renal allograft outcomes of transplant recipients with TMA. Moreover, the usual presence of multiple overlapping triggers supports the hypothesis that, in post transplant setting, several factors can act synergistically to injure the graft endothelium. We also highlight that ABMR is the most important limiting factor for graft survival in patients with TMA.

The low incidence of post-transplant TMA in our center is in accordance with what was reported in larger series as the study of Reynolds *et al* \[[@pone.0227445.ref004]\]. Differences in TMA diagnostic criteria- based on clinical, laboratorial or histological grounds- and patients' selection- percentage of sensitized recipients and with HUS as cause of primary disease- could explain the wide range of incidence rates seen in the literature. \[[@pone.0227445.ref002]--[@pone.0227445.ref006]\]

The baseline characteristics of our cohort, composed mainly by young and female recipients that received a kidney from a deceased donor, corroborate the results previously published \[[@pone.0227445.ref004],[@pone.0227445.ref005],[@pone.0227445.ref025]\] that suggest these are risk factors for development of post-transplant TMA. Genetic and hormonal factors could explain the particular susceptibility of these individuals to TMA in an environment with other endothelial aggressors as CNI and ischemia-reperfusion injury. \[[@pone.0227445.ref009]\] We caution that, due the high proportion of patients with primary kidney disease of unknown etiology in our data, we cannot fully ascertain whether some cases of recurrent aHUS were misdiagnosed as *de novo* TMA.

In a slim majority of the patients, TMA occurred in the early period, although there was a great variability of time of onset. These findings are in general agreement with the observations of Reynolds *et al* \[[@pone.0227445.ref004]\] that shows that, in spite of the fact that the incidence peak of *de novo* and recurrent TMA occurs in the first 6 months, the risk continues afterward. Theses results should be interpreted as an alert that TMA can be cause of allograft dysfunction at any period of post-transplantation. Furthermore, in our cohort, the timing of TMA diagnosis was not correlated to difference in rate of graft loss, in contrast to what published elsewhere \[[@pone.0227445.ref025]\].

Systemic TMA occurred in less than one third of the case, which is consistent with study selection criteria based in biopsy-proven TMA. The presence of hemolysis was not associated with graft failure or worse graft function, likewise the data published by Schwimmer *et al*. \[[@pone.0227445.ref003]\] It is unclear whether this is because systemic TMA is associated with more severe dysfunction at the moment of the diagnosis, leading to an earlier biopsy, diagnosis and therapy.

The evidence of ABMR associated to TMA was less common at our institution, compared to what described in other series (Satoskar *et al*, 55%, Wu *et al* 52% vs. 13%). \[[@pone.0227445.ref002],[@pone.0227445.ref026]\] This can be explained by the low percentage of sensitized and re-transplanted in our patients. Nevertheless, patients who had ABMR were significantly more likely to have graft failure, as highlighted before by Wu *et al*. \[[@pone.0227445.ref026]\]

Beyond that, despite the prevalence of pre-transplant AT1R antibodies in serum samples of our patients was similar to what was published in literature, two patients had an ABMR-TMA due to AT1R antibodies emphasizing the hypothesis that these non-HLA (human leukocyte antigen) antibodies may be associated to microvascular inflammation, early acute rejection and allograft loss as previously reported. \[[@pone.0227445.ref027]--[@pone.0227445.ref029]\]

TMA associated only to drug toxicity was relatively infrequent in our findings, compared to what was observed by Nava *et al*. \[[@pone.0227445.ref030]\]. On the other hand, in accordance with what was recently published by Bayer *et al* \[[@pone.0227445.ref031]\], the usual presence of multiples conditions causing or precipitating TMA supports the \"multiple hit hypothesis\" \[[@pone.0227445.ref008],[@pone.0227445.ref032]\] that speculates that TMA is the consequence of the combination of genetic predisposition and several trigger factors/conditions in both native and transplanted kidneys.

Although eculizumab, a C5-targeted complement blocker, is very promise in prophylaxis and treatment for recurrent aHUS after kidney transplantation \[[@pone.0227445.ref033],[@pone.0227445.ref034]\], it was not a therapeutic option in our cohort, since, in Brazil\'s publicly funded health care system, it is only available for treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). \[[@pone.0227445.ref035],[@pone.0227445.ref036]\] The high cost of medication and need for prolonged treatment preclude the financing of this therapy by the local transplant centers or the patient itself.

The high rate of renal allograft loss in our cohort is probably related to the unspecific therapeutic approach performed, explained by the unavailability of complement blockers and diagnostic tools for differentiation of the etiologies and triggers of post-transplant TMA.

Regarding the histological features, the thrombi location had no predictive value for graft failure in our study, which is consistent with the results of Satoskar *et al* \[[@pone.0227445.ref002]\] but is in disagreement with what have been published by Wu et *al* \[[@pone.0227445.ref025]\], where the pattern and severity of vasculopathy of TMA were associated to poor allograft outcomes. The presence of endothelial cell activation in the allograft biopsy diagnostic of TMA was also not associated to a higher risk of allograft loss. We hypothesize that endothelial damage probably is a more determinant matter if it occurs in a chronic and continuous fashion as seen in transplant glomerulopathy \[[@pone.0227445.ref006],[@pone.0227445.ref037],[@pone.0227445.ref038]\].

This study has some limitations inherent to its retrospective methodology, such as rigorous diagnosis workup not always available, selection criteria based on histological TMA diagnosis and small sample sized, that precludes drawing definitive conclusions. Other issue that needs consideration is the lack of complement mutational analysis. However it would be interesting to reveal the individual predisposing factors, current evidence does not support evaluation of the complement system in all patients with *de novo* TMA \[[@pone.0227445.ref011]\]. On the other hand, our study is the first to relate several clinical and histological features of biopsy-proven TMA in kidney-transplanted patients.

In summary, our data suggest that TMA is a rare but severe condition in the setting of renal transplant, regardless of its clinical or pathological presentation. When associated to ABMR, its prognosis is even worse. It is important to recognize that the lack of a tailored therapeutic strategy, as the complement blockade, partially accounts for the bad outcomes of our findings. Further prospective studies carefully looking at the impact of this treatment are required to test this hypothesis.

The authors gratefully thank the patients and nursing staff who participated in this study.

TMA

:   thrombotic microangiopathy

ABMR

:   antibody mediated rejection

aHUS

:   atypical hemolytic uremic syndrome

CNI

:   calcineurin inhibitor

IF/TA

:   interstitial fibrosis and tubular atrophy

TCMR

:   acute cellular rejection

TTP

:   thrombocytopenic thrombotic purpura

eGFR

:   estimated glomerular filtration rate

CKD-EPI

:   chronic kidney disease epidemiology collaboration

DIC

:   disseminated intravascular coagulation

PRA

:   panel-reactive antibodies

mTOR

:   mammalian target of rapamycin

AT1R

:   angiotensin II type 1 receptor

HELLP

:   hemolysis, elevated liver enzymes and low platelets

HLA

:   human leukocyte antigen

PNH

:   paroxysmal nocturnal hemoglobinuria (PNH)
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Dear Mrs Teixeira,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

**The manuscript focuses on a topic of potential interest. There are, however, few shortcomings in the study the authors should address. To mention few of them, i) need to expand more the conclusions; ii) need to discuss about the high rate of allograft loss and potential causes of this; iii) need to include in the method section how the cases are reviewed for the diagnosis of TMA prior to the confirmation by reviewing kidney biopsies; iv) need to include the methods of their search such as \"CPT codes\" used; v) need to clarify if dialysis was temporary; vi) concern about the statement that their cohort suggest risk factors for development of de novo TMA; vii) need to implement the discussion about eculizumab therapy and its use in Brazil, if any**.

We would appreciate receiving your revised manuscript by Nov 16 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.
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1\. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

2\. Thank you for including your ethics statement: The study protocol was approved by the institutional review board (CEP-UNIFESP-parecer 1643995) and adheres to the 2000 Declaration of Helsinki as well as the Declaration of Istanbul 2008. The consent was not obtained because the data were analyzed retrospectively and anonymously.

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

3\. Thank you for including your competing interests statement; \"I have read the journal\'s policy and the authors of this manuscript have the following competing interests: Dr. HTS reports grants and personal fees from NOVARTIS, grants and personal fees from PFIZER, grants and personal fees from SANOFI and grants from QUARK, outside the submitted work. All the other authors declared no relevant competing interests. \"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.
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4\. Please include a copy of Table 5 which you refer to in your text on page 18
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Line 71 and Line 510: I would change the verb \"prove\" to \"suggest\" in the conclusion. And it would be beneficial for the authors to expand more on their conclusions. They should discuss about the high rate of allograft loss and potential causes of this.

In the methods section, they should include how the cases were reviewed for the diagnosis of TMA prior to the confirmation by reviewing kidney biopsies, and include the methods of their search such as \"CPT codes\" used or explained how they found/ collected 119 cases with diagnosis of TMA (how was this original diagnosis made).

And this should be included as a limitation in the discussion part.

Line 248, Authors mention that over one third of patients were on dialysis, please clarify if dialysis was temporary or if there was allograft loss within the first 3 months post transplant.

Lines 446-449. Authors imply that their cohort suggest risk factors for development of de novo TMA, but without not know the primary disease of ESRD 37% on the cohort, it is hard to make a conclusion of de novo presentation. This should be clarified in this paragraph.

In the discussion, the authors should also include the lack of therapy with eculizumab in their cohort, and should recognize this drug as part of the therapy for aHUS worldwide, and perhaps disclose if this medication is not routinely used in Brazil at the moment (due to cost or other reasons, this should also be explained)

Reviewer \#2: The authors have conducted a thorough retrospective review of 89 kidney transplant patients with TMA and classified their clinical and pathological findings in detail. the main observation of the study is the TMA associated with ABMR has a considerably poorer prognosis than TMA not associated with ABMR. The pathologic features did not play as large a role in differentiating outcomes with respect to dGFR.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Stuart J. Knechtle

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Academic Editor and reviewers,

Please find enclosed the corrected version of the manuscript entitled "Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes". The answers to the reviewers are disposed bellow.

1\. need to expand more the conclusions

It is important to recognize that the lack of a tailored therapeutic strategy, as the complement blockade, partially accounts for the bad outcomes of our findings. Further prospective studies carefully looking at the impact of this treatment are required to test this hypothesis.

This statement was added on "Discussion" section.

2\. need to discuss about the high rate of allograft loss and potential causes of this

The high rate of renal allograft loss in our cohort is probably related to the unspecific therapeutic approach performed, explained by the unavailability of complement blockers and diagnostic tools for differentiation of the etiologies and triggers of post-transplant TMA.

This statement was added on "Discussion" section.

3\. need to clarify if dialysis was temporary

At the time of TMA diagnosis, 36% of the patients (n=32) were on dialysis. There was allograft loss within the first 3 months post transplant in 13 patients.

This information was written in "Results" section.

4\. concern about the statement that their cohort suggest risk factors for development of de novo TMA

We caution that, due the high proportion of patients with primary kidney disease of unknown etiology in our data, we cannot fully ascertain whether some cases of recurrent aHUS were misdiagnosed as de novo TMA.

We added this caveat on "Discussion" section and suppressed the expression "de novo" of the sentence on line 457.

5\. need to implement the discussion about eculizumab therapy and its use in Brazil, if any.

Although eculizumab was not a therapeutic option in our cohort, since, in Brazil\'s publicly funded health care system, it is only available for treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The high cost of medication and need for prolonged treatment preclude the financing of this therapy by the local transplant centers or the patient itself.

We addressed this issue on "Discussion" section.

6\. Review Line 71 and Line 510: I would change the verb \"prove\" to \"suggest\" in the conclusion.

Thank you. We changed the verb.

7\. In the methods section, they should include how the cases were reviewed for the diagnosis of TMA prior to the confirmation by reviewing kidney biopsies, and include the methods of their search such as \"CPT codes\" used or explained how they found/ collected 119 cases with diagnosis of TMA (how was this original diagnosis made).

And this should be included as a limitation in the discussion part.

In Brazil or Hospital do Rim, the search for CPT codes is not available. In this retrospective cohort study, we initially retrieved all consecutive unselected reports of renal transplant biopsies from Hospital do Rim database between January 2011 and December 2015. These biopsies were performed for graft dysfunction, new onset proteinuria or delayed graft function from kidney and kidney-pancreas transplanted patients. Of a total of 6886, we selected 119 biopsies whose reports described features of TMA. Final diagnosis was confirmed by one of the pathologist authors (LARM).

We added this information on "Methodology" section. In addition, we wrote a statement on "Discussion" section addressing the possible selection criteria bias as a limitation of our study, since TMA diagnosis was based only on histological criteria.

8\. Please include a copy of Table 5 which you refer to in your text on page 18

On page 18 line 367, there was a typing error: there is no Table 5. The results are related to Table 4, instead. We are sorry about it.

9\. Additional requirements

We amended current and reviewed statements about ethics and competing interests in the manuscript and in the online submission form.

I hope this new version will fit the requirements for publication in PLOS ONE.

I am looking forward to hearing from you soon.

Sincerely,

Dr. Cínthia Montenegro Teixeira, the corresponding author
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Very interesting topic. Authors have answered in detail comments made by this reviewer. I have no other comments to add at this moment.

Reviewer \#2: There are several examples of words that are used incorrectly and need to be edited, but the content of the paper is excellent and the authors have responded to the reviewers\' concerns.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Stuart Knechtle
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